All stock lists
Ionis Pharmaceuticals Inc (NASDAQ:IONS)
US · Delayed Price · Currency is USD
Also listed: 0JDI.LHealthcare · Biotechnology
43.42+0.49 (+1.14%)
Market cap
$7.22B
Health Score
Analyst consensus
Listed since
May 17, 1991
Website
Insider Score
––Not scored
IONS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
IONS analyst forecast
IONS analyst consensus
Moderate Buy11 ratings
Buy 10 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
IONS 12-month price target
$83.80+93.0% upsideaverage of 5 firms
$104.00High
$66.00Low
Best analysts covering IONS
- Raymond James100%success rate · 1 call
- HC Wainwright & Co.75%success rate · 8 calls
- Wells Fargo75%success rate · 4 calls
- Guggenheim67%success rate · 6 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
IONS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| BMO Capital | Outperform | $66.00 | +49.1% | Upgraded | 2026-10-22 | |
| — | UBS | Buy | — | — | Upgraded | 2026-10-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-24 |
| Oppenheimer | — | $85.00 | +93.5% | — | 2026-09-24 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-09-22 |
| Guggenheim | Buy | $80.00 | +55.5% | Reiterated | 2026-09-15 | |
| — | Barclays | Overweight | — | — | Reiterated | 2026-09-09 |
| — | BMO Capital | Market Perform | — | — | Reiterated | 2026-09-08 |
| Morgan Stanley | Overweight | $104.00 | +83.4% | Reiterated | 2026-09-08 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-08 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-09-08 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2026-09-08 |
| Raymond James | — | $84.00 | +48.9% | — | 2026-09-08 | |
| BMO Capital | Market Perform | $61.00 | +4.9% | Reiterated | 2026-09-04 | |
| — | Needham | Buy | — | — | Reiterated | 2026-09-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-31 |
| — | BMO Capital | Market Perform | — | — | Downgraded | 2026-08-19 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-08-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-30 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-07-30 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-07-21 |
| — | Wolfe Research | Peer Perform | — | — | Downgraded | 2026-07-16 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-07-13 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-07-10 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-07-10 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-07-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-10 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-07-10 |
| — | Jefferies | Buy | — | — | Reiterated | 2026-07-09 |
| — | Needham | Buy | — | — | Reiterated | 2026-07-09 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-06-25 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2026-06-25 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-25 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-06-17 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-06-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-04-30 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2026-04-30 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-04-30 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-04-23 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-04-21 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-04-09 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-03-26 |
| — | Needham | Buy | — | — | Reiterated | 2026-03-25 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-25 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-03-03 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-02-27 |
| — | Needham | Buy | — | — | Reiterated | 2026-02-26 |
| — | Stifel | Hold | — | — | Reiterated | 2026-02-26 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-02-06 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-01-05 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-12-17 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2025-12-15 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-12-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-10 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-11-04 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-10-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-30 |
IONS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-25 | -1.24 | -1.41 | $156.1M | $203.0M |
| 2026-04-29 | -0.85 | -0.56 | $195.6M | $246.0M |
| 2026-07-29 | -1.09 | -0.69 | $189.1M | $268.0M |
| 2026-11-04 | -1.22 | 0.00 | $181.6M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.